What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
This Boston-based biotech, focused on bifunctional antibody therapies for cancer, just reported a notable insider sale in recent filings.
Overview
Claire Mazumdar, Chief Executive Officer of Bicara Therapeutics Inc. (NASDAQ:BCAX), reported the exercise of 15,000 stock options with immediate sale of the resulting common shares on May 18, 2026, as disclosed in the SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average reported price ($20.04); post-transaction value based on May 18, 2026 market close.
Details
* 1-year performance calculated using May 18th, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.